Redwire Subsidiary SpaceMD Contracts with SpaceX to Fly PIL-BOX Crystallization Mini-Labs on Starfall Re-entry Capsule

September 6, 2026

ISS National Lab USA

Overview

Redwire subsidiary SpaceMD has contracted with SpaceX to fly PIL-BOX crystallization mini-labs on the Starfall re-entry capsule. This initiative builds upon the success of over 50 PIL-BOX mini-labs flown on the International Space Station (ISS) since 2023. The agreement allows for continued microgravity drug compound crystallization experiments and rapid sample return to Earth, accelerating the utilization of space in pharmaceutical development.

In Depth

Key Findings

SpaceMD, a subsidiary of Redwire, has entered into an agreement with SpaceX to fly its PIL-BOX crystallization mini-labs aboard the Starfall re-entry capsule. This contract builds upon the successful operation of over 50 PIL-BOX mini-labs that have been deployed on the International Space Station (ISS) since 2023.

Technical and Operational Details

PIL-BOX Mini-Labs: The PIL-BOX (Protein In-Liquid Box) mini-labs are autonomous, compact experimental devices designed to study the growth of protein and other pharmaceutical compound crystals in a microgravity environment. The objective is to produce larger, purer, and more ordered crystals in space, which are often difficult to achieve under Earth’s gravitational conditions.
Utilization of Starfall Re-entry Capsule: SpaceX’s Starfall capsule offers a rapid and safe return capability for samples from orbit back to Earth once experiments are completed. This minimizes the risk of compromising the quality of microgravity-grown drug crystals during the re-entry process, enabling researchers to analyze samples in a timely manner.
Continued Experimentation and Expansion: This agreement allows SpaceMD to leverage its successful experience on the ISS to continue and expand microgravity drug crystallization research. The focus will be on a broader range of pharmaceutical compounds, exploring the commercial potential of microgravity environments for drug development.

Background and Industry Context

Pharmaceutical manufacturing in microgravity is rapidly gaining attention as a new frontier in the drug industry. Earth’s gravity can induce convection in protein solutions, leading to non-uniform crystal growth and defects. In microgravity, these effects are eliminated, increasing the likelihood of producing higher-quality crystals. Such high-quality crystals can lead to improved drug structural elucidation, formulation development, and ultimately, the creation of more effective and safer medicines. With other companies like Varda Space and BioOrbit entering this domain, in-space pharmaceutical manufacturing is becoming a significant segment of the space economy.

Strategic Significance and Outlook

SpaceMD’s flights of PIL-BOX mini-labs on the Starfall capsule will accelerate microgravity drug crystallization research and further enhance its commercial viability. The rapid sample return capability can shorten experimental cycles and accelerate the pace of pharmaceutical development. This has the potential to reduce the time from drug discovery to clinical application, benefiting more patients worldwide. Furthermore, Redwire is solidifying its position as a leading provider of advanced in-space manufacturing solutions, expected to spearhead the emerging industry of pharmaceuticals produced from space.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.